skip to main content

Mesalazine renal monitoring — GPhC CRA MCQ

Instant feedback + full explanation. One question, done properly.

HardGI TherapeuticsMesalazine renal monitoringGPhC CRA

A 43-year-old man with ulcerative colitis takes mesalazine modified-release tablets. His repeat request is early because he lost tablets while travelling; recent records show no renal function test for 14 months. What monitoring is required?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Renal function monitoring should be arranged during ongoing mesalazine therapy

Mesalazine can rarely cause renal impairment, so renal function should be checked before and during treatment. An absent monitoring record for over a year should be flagged, especially with ongoing repeat supply. INR, lithium and glucose monitoring are not standard mesalazine requirements unless other medicines or conditions indicate them. The lost supply can be addressed, but safety monitoring should not be ignored.

Reference: BNF; NICE CKS Ulcerative colitis